PubMed COVID-19 Clinical Care

Coronavirus disease 2019 (COVID-19) vaccine hesitancy is a major concern in this pandemic context. This study postulates that vaccine hesitancy among individuals might be associated with a high state of decisional conflict which indicates a state of

No abstract

CONCLUSION: This study gave deeper insight into the schools of thought which will be important in designing future interventions and yoga-meditation based programs in the future, essentially for geriatric populations as it serves as a feasible simple

CONCLUSION: This study gave deeper insight into the schools of thought which will be important in designing future interventions and yoga-meditation based programs in the future, essentially for geriatric populations as it serves as a feasible simple

CONCLUSION: This study gave deeper insight into the schools of thought which will be important in designing future interventions and yoga-meditation based programs in the future, essentially for geriatric populations as it serves as a feasible simple

BackgroundGreat efforts have been made to minimise spread and prevent outbreaks of COVID-19 in hospitals. However, there is uncertainty in identifying nosocomial vs community-acquired infections. To minimise risks and evaluate measures, timely data

The COVID-19 pandemic has been observed to negatively affect older adults' psychological health compared with prepandemic levels. However, older adults' coping efficacy may differ depending on their age, and little is known about effects of

In this study we analyzed data collected from the onset of the COVID-19 pandemic through March 31, 2022 to identify temporal shifts in breast exam volume. Screening mammography volume stabilized toward the end of the study period, while diagnostic

CONCLUSION: Our study suggests that genetically determined hypertension may increase the risk for severe COVID-19. The shared genetic variation and the connecting molecular pathways may underline causal links between hypertension and COVID-19. This

CONCLUSION: Baricitinib significantly improves clinical outcomes in hospitalized patients with COVID-19 pneumonia, and further evidence will establish the drug as a standard treatment among such patients.